BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 19, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2008

View Archived Issues

Positive results emerge from phase III ALO-01 study in patients with osteoarthritis pain

Read More

rhEPO shows clinical benefits for the treatment of amyotrophic lateral sclerosis

Read More

Cenomed reports on new schizophrenia and posttraumatic stress disorder candidates

Read More

Mutation-specific effects seen with pyrimethamine in familial ALS patients

Read More

Novel means of avoiding opioid-related adverse events reported in recent Progenics patent

Read More

Recent GenkyoTex patent imparts novel therapeutics for cardiovascular disorders

Read More

New antiinflammatory agents reported in recent Biolipox patents

Read More

Alizyme presents update on clinical development activities between July and November 2008

Read More

FDA reschedules Advisory Committee meeting with Novo for liraglutide until April 2009

Read More

Memory completes enrollment in phase II trial of MEM-3454 in CI associated with schizophrenia

Read More

CytRx updates progress of third quarter 2008

Read More

Chelsea Therapeutics completes enrollment in phase II trial of droxidopa in IDH

Read More

GenVec reports interim results from phase III PACT trial of TNFerade

Read More

Phase III studies show vandetanib offers benefit to patients with lung cancer

Read More

BioDelivery Sciences to resubmit REMS for Onsolis to FDA in December 2008

Read More

Karo Bio and Wyeth extend drug discovery collaboration with LXR in inflammatory diseases

Read More

BI-201335 well tolerated, active in treatment-naive and -experienced HCV patients

Read More

Hyperphosphatemia controlled with fermagate in hemodialysis patients

Read More

Elixir's reports results from phase III trial of metformin-mitiglinide therapy

Read More

Telavancin receives favorable recommendation from FDA

Read More

Cougar Biotechnology commences phase I/II CB-7630 trial in breast cancer

Read More

Ortho Biotech submits NDA for trabectedin for relapsed ovarian cancer

Read More

Debiopharm and Aurigene sign licensing agreement for Debio-0617

Read More

Grazax approved in Europe for children with hay fever

Read More

Basilea's Zevtera receives positive opinion from the CHMP

Read More

GlaxoSmithKline receives FDA accelerated approval for Promacta

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing